Axcynsis Therapeutics Pte Ltd. has described antibody-drug conjugates comprising an antibody or antigen-binding fragment targeting alkaline phosphatase placental type (ALPP) and/or alkaline phosphatase, germ cell type (ALPPL2) covalently linked to a cytotoxic agent through a linker reported to be useful for the treatment of cancer.

Forx Therapeutics AG has divulged poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.

Revagenix Inc. has identified aminoglycosides reported to be useful for the treatment of bacterial infections.

Pinotbio Inc. has synthesized camptothecin derivatives and its antibody-drug conjugates reported to be useful for the treatment of cancer.

Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed Toll-like receptor 7 (TLR7) and/or TLR8 and/or TLR9 antagonists reported to be useful for the treatment of rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus and Sjögren’s syndrome.

Shanghai Allist Pharmaceuticals Co. Ltd. has described phosphatidylinositol 3-kinase α (PI3Kα, H1047R mutant) allosteric inhibitors reported to be useful for the treatment of cancer.

Beigene Switzerland GmbH has divulged CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.

Sanofi SA has identified GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Shenzhen Zhongge Biotechnology Co. Ltd. has synthesized serine/threonine-protein kinase ULK1 inhibitors reported to be useful for the treatment of cancer, lymphangioleiomyomatosis and tuberous sclerosis.